Technology ID
TAB-4070

Human Synovial Sarcoma Cell Line A2243

E-Numbers
E-160-2005-0
Lead Inventor
Aaronson, Stuart (NCI)
Co-Inventors
Ellmore, Nelson (NCI)
Applications
Research Materials
Therapeutic Areas
Oncology
Development Stages
Discovery
Lead IC
NCI
ICs
NCI

Synovial sarcoma is a cancer affecting mesenchymal cells in connective tissues. This rare cancer is typically linked to genetic abnormalities or exposure to radiation. Metastatic growth throughout the body can occur primarily through blood circulation. More than 90% of synovial sarcomas show a characteristic t(X;18)(p11;q11) translocation involving the SYT and SSX genes. The resulting SYT-SSX abnormal fusion protein causes misregulation of downstream gene expression, leading to tumor formation.

Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology (LCMB), have derived a cell line, A2243, from a patient with human synovial sarcoma. This cell line forms tumors in nude mice. The A2243 cell line has been used to characterize the abnormal karyotype associated with synovial sarcoma. Additionally, the A2243 cell line has been used to discover the gene involved in recurrent chromosomal translocation.

NCI is seeking parties to non-exclusively license the A2243 human synovial sarcoma cell line.

Competitive Advantages:

  • Well-characterized cell line for a rare human cancer: synovial sarcoma

 

Commercial Applications:

  • Research tool for drug screening efforts
  • Research tool for identifying general and specific chromosomal translocations in synovial sarcoma

 

Request More Info

Licensing Contact:
Gulay French, Suna
suna.gulay@nih.gov

Publications

Collaborations

  • Licensing
Date Published
Date Updated